Has the Swiss Pharma Industry valuation changed over the past few years?

Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PE ratio of 22.5x. The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.7x.

Which industries have driven the changes within the Swiss Healthcare industry?

There are no additional sub-industries under this industry.

Swiss (SMI) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 08 Jul 2026	CHF 571.3b	CHF 122.7b	CHF 25.1b	36.7x	22.8x	4.7x
Fri, 05 Jun 2026	CHF 541.4b	CHF 121.5b	CHF 24.8b	38.1x	21.8x	4.5x
Sun, 03 May 2026	CHF 547.2b	CHF 120.9b	CHF 24.7b	37.9x	22.1x	4.5x
Tue, 31 Mar 2026	CHF 547.1b	CHF 122.3b	CHF 25.4b	35.8x	21.6x	4.5x
Thu, 26 Feb 2026	CHF 614.7b	CHF 119.6b	CHF 24.3b	37.1x	25.3x	5.1x
Sat, 24 Jan 2026	CHF 589.2b	CHF 120.5b	CHF 21.4b	36.9x	27.5x	4.9x
Mon, 22 Dec 2025	CHF 556.4b	CHF 121.1b	CHF 21.5b	33.6x	25.9x	4.6x
Wed, 19 Nov 2025	CHF 521.7b	CHF 121.3b	CHF 21.6b	33.8x	24.2x	4.3x
Fri, 17 Oct 2025	CHF 506.2b	CHF 119.9b	CHF 20.9b	33.5x	24.3x	4.2x
Sun, 14 Sep 2025	CHF 479.5b	CHF 120.2b	CHF 20.9b	31.8x	22.9x	4x
Tue, 12 Aug 2025	CHF 454.3b	CHF 121.2b	CHF 21.0b	22.2x	21.7x	3.7x
Thu, 10 Jul 2025	CHF 454.3b	CHF 117.1b	CHF 18.9b	25x	24.1x	3.9x
Sat, 07 Jun 2025	CHF 457.0b	CHF 119.0b	CHF 19.3b	25.8x	23.7x	3.8x
Mon, 05 May 2025	CHF 446.5b	CHF 119.2b	CHF 19.3b	26.2x	23.2x	3.7x
Wed, 02 Apr 2025	CHF 463.1b	CHF 121.8b	CHF 19.2b	28.1x	24.1x	3.8x
Fri, 28 Feb 2025	CHF 479.4b	CHF 122.3b	CHF 19.1b	23.3x	25.1x	3.9x
Sun, 26 Jan 2025	CHF 450.4b	CHF 119.4b	CHF 21.4b	18.8x	21.1x	3.8x
Tue, 24 Dec 2024	CHF 420.4b	CHF 119.0b	CHF 21.3b	17.7x	19.7x	3.5x
Thu, 21 Nov 2024	CHF 424.2b	CHF 118.0b	CHF 21.1b	18.1x	20.1x	3.6x
Sat, 19 Oct 2024	CHF 464.3b	CHF 115.8b	CHF 19.5b	22x	23.8x	4x
Mon, 16 Sep 2024	CHF 451.0b	CHF 114.8b	CHF 19.3b	21.6x	23.4x	3.9x
Wed, 14 Aug 2024	CHF 460.3b	CHF 115.8b	CHF 19.5b	21.8x	23.6x	4x
Fri, 12 Jul 2024	CHF 443.6b	CHF 116.3b	CHF 19.8b	34.3x	22.5x	3.8x
Sun, 09 Jun 2024	CHF 426.0b	CHF 116.3b	CHF 19.8b	44.1x	21.6x	3.7x
Tue, 07 May 2024	CHF 390.5b	CHF 113.2b	CHF 19.9b	39.5x	19.6x	3.5x
Thu, 04 Apr 2024	CHF 400.8b	CHF 112.0b	CHF 19.4b	36.8x	20.7x	3.6x
Sat, 02 Mar 2024	CHF 388.1b	CHF 110.5b	CHF 19.7b	24.3x	19.7x	3.5x
Mon, 29 Jan 2024	CHF 413.8b	CHF 120.2b	CHF 18.8b	27x	22.1x	3.4x
Wed, 27 Dec 2023	CHF 394.7b	CHF 119.7b	CHF 18.7b	25x	21.1x	3.3x
Fri, 24 Nov 2023	CHF 391.8b	CHF 121.4b	CHF 18.9b	24.6x	20.7x	3.2x
Sun, 22 Oct 2023	CHF 390.9b	CHF 120.9b	CHF 18.6b	25.7x	21.1x	3.2x
Tue, 19 Sep 2023	CHF 410.0b	CHF 112.7b	CHF 18.0b	46.4x	22.7x	3.6x
Thu, 17 Aug 2023	CHF 408.0b	CHF 111.7b	CHF 17.9b	48.3x	22.8x	3.7x
Sat, 15 Jul 2023	CHF 408.4b	CHF 113.3b	CHF 18.6b	36.9x	21.9x	3.6x


CH Market	0.62%
Healthcare	-0.73%
Pharma	-1.78%
Pharma	-1.78%

Company	Last Price	7D	1Y	Valuation
ROP Roche Holding	CHF 339.50	2.0% +CHF 5.3b	31.7%	PE21x
NOVN Novartis	CHF 126.80	0.2% +CHF 402.7m	29.8%	PE21.2x
COPN Cosmo	CHF 67.70	1.8% +CHF 19.4m	9.2%	PS11.4x
CURN Curatis Holding	CHF 23.00	3.6% +CHF 4.2m	101.8%	PS11.3x
BIOV BioVersys	CHF 27.20	2.6% +CHF 4.1m	-24.0%	PS50.2x

Announcement • 8h

Roche Presents New Data in Alzheimer’S Disease Portfolio At Aaic 2026

Roche announced that it will present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference 2026 (AAIC) in London on 12-15 July. These data demonstrate how Roche is advancing the development of next-generation medicines and diagnostic tests. There are 18 oral and poster presentations. Highlights include five oral presentations as part of a trontinemab Featured Research Session, an oral Perspectives Session on neuroimmune targets such as NLRP3 for neurodegenerative diseases, and presentations on the use of Roche's Elecsys pTau217 and pTau181 blood tests to support Alzheimer’s disease diagnosis. Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody. Presenters will share new long-term safety, amyloid removal and biomarker data from the Phase Ib/IIa Brainshuttle AD open-label extension study. Modelling from this study has informed the dosing regimen for the ongoing Phase III TRONTIER 1 and 2 studies in early symptomatic Alzheimer’s disease. Roche will also share the design of PrevenTRON, a Phase III study investigating trontinemab in preclinical Alzheimer’s disease. PrevenTRON is planning to recruit cognitively unimpaired individuals at high risk of progression to symptomatic Alzheimer’s, and investigators are using Roche’s Elecsys pTau217 blood test to help identify potential study participants. AAIC has invited Roche to present a Perspectives Session on the NLRP3 inflammasome in Alzheimer’s disease. Emerging preclinical and clinical data on the immunomodulatory effects of NLRP3 inhibition in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease will also be presented. Roche’s Elecsys pTau217 blood test recently received CE mark certification as both a rule-in and rule-out test of amyloid pathology to aid in Alzheimer’s disease diagnosis, and data will be presented evaluating the test’s performance in primary and secondary care settings. New data will be presented for the approved Elecsys pTau181 blood test for ruling out Alzheimer’s disease, which explores sample stability under different storage conditions and test performance across large, diverse, cognitively impaired patient populations to support implementation of the test in routine clinical practice. Roche is sponsoring a symposium “Closing the Diagnostic Gap: Utilizing pTau217 for Scalable Alzheimer’s Disease Diagnosis” on Sunday 12 July at 12:30-13:45 BST at the Crowne Plaza London Docklands Hotel. The symposium will discuss the evolving role of blood-based biomarkers in the early detection and diagnosis of Alzheimer’s disease, including the potential of scalable blood testing approaches designed to help reduce diagnostic barriers, enable earlier identification of individuals at risk, and support broader access to disease-modifying therapies in clinical practice. Trontinemab Long-Term Safety and Amyloid Removal with Trontinemab: Interim Data from the Open-Label Extension of the Phase Ib/IIa Brainshuttle AD Study. Interim Long-Term Biomarker Results from the Trontinemab Open-Label Extension of the Phase Ib/IIa Brainshuttle AD Study. Simulation of Amyloid Clearance in Phase III Studies with Trontinemab in Early Symptomatic Alzheimer’s Disease. Evidence Supporting Preclinical AD as an Optimal Stage for Intervention with Trontinemab. PrevenTRON: Rationale and Design of a Phase III Trial of Trontinemab in Cognitively Unimpaired Individuals with Biomarkers of Alzheimer’s Disease at High Risk of Clinical Decline. The Role of NLRP3 in Alzheimer's Disease: Reverse Translational Data from GRADUATE Ph3 Trials. Investigating the Role of the NLRP3 Inflammasome in the Pathogenesis of Alzheimer’s Disease. External Controls Vs. Observed Placebo: How Close Can We Get? GRADUATE I and II Results. Tau Pathology Interferes with Amyloid Removal by Gantenerumab. Burden and Support Needs of Informal Caregivers of People Living with Alzheimer’s Disease in Three Countries. Mental Health Conditions in Spouses of People Living with Alzheimer's Disease: A Longitudinal US Claims Data Analysis. Expanding Clinical Trial Access to Underrepresented Populations in the U.S.: Findings from the Alzheimer’s Disease Pre-Screener Study. A Low-Burden Cognitive Prescreening Protocol for Enhanced Diversity and Recruitment in Roche’s Alzheimer’s Disease Clinical Trials. Rule-Out Performance of a Plasma pTau181 Immunoassay at Established Cutoffs in Subgroups Across a Large, Diverse, Cognitively Impaired Population. Evaluating a Future In Vitro Diagnostic pTau217 Plasma Assay for the Detection of Amyloid Pathology in Primary and Secondary Care Settings. Elecsys pTau181 Plasma Immunoassay Performance Against Centiloid-Based Amyloid Classification Across Clinical Stages. Elecsys Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid-Positron Emission Tomography in a Chinese Population. Sample Stability for a New pTau181 Plasma Immunoassay: Implications for Rule-Out Testing for Alzheimer’s Disease in Routine Clinical Practice.

Announcement • Jul 01

Sandoz Group AG Receives US FDA File Acceptances for Generic Tirzepatide Autoinjector Applications

Sandoz Group AG received US FDA file acceptances for generic tirzepatide autoinjector applications. Proposed generic tirzepatide was developed in-house by Sandoz. Applications address same indications covered by reference medicines, including type-2 diabetes and weight management. The ANDAs seek approval for an in-house Sandoz generic version of the tirzepatide autoinjector, a generic gastric inhibitory polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Both applications, which were filed under the FDA's generic pathway, address all indications of the reference medicines, Mounjaro and Zepbound. For Mounjaro, this would be as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients 10 years of age and older with type 2 diabetes mellitus. For Zepbound, this would be in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in obese or overweight adults in the presence of at least one weight-related comorbid condition and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity for weight management. Subject to FDA approval, Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the US on market formation. Generic tirzepatide was developed in-house at Sandoz, combining the Company's expertise in small molecule and device development with its biosimilar expertise for advanced techniques. The GLP-1 treatment area represents a long-term market opportunity, complementing the broader growth outlook for biosimilar and generic medicines. Reference medicines with a combined value of more than USD 650 billion are expected to lose patent protection over the next decade. Sandoz is developing a competitive GLP-1 pipeline across key global markets, addressing each opportunity with a mix of internal capabilities and strategic external partnerships across development and manufacturing. Sandoz is committed to helping millions of patients access critical and potentially life-changing medicines sustainably and affordably, with a leading global portfolio comprising 1,300 quality generics and a further 400 generic assets in various stages of development.

Swiss (SMI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Roche Presents New Data in Alzheimer’S Disease Portfolio At Aaic 2026

COPN: Late-Stage Alopecia Data And Higher Assumptions Will Support Future Earnings Potential

Novartis AG (SWX:NOVN) entered into an agreement to acquire Myricx Pharma Ltd from Sofinnova Partners SAS and others for $1.5 billion.

Consensus EPS estimates increase by 14%

FDA Delays Galderma Botox Alternative on Manufacturing Concerns

Sandoz Group AG Receives US FDA File Acceptances for Generic Tirzepatide Autoinjector Applications

Curatis Holding AG Increases Earnings Guidance for the Financial Year 2026

Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026

Still A Binary Phase III Bet on Evenamide

Bioversys Ag Approves Election of Simona Skerjanec as Members of the Board of Directors